MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) and Caraway Therapeutics, Inc. announced that the companies have entered into a definitive agreement under which MSD, through a subsidiary, will acquire Caraway Therapeutics for a total potential consideration of up to $610 million, including an undisclosed upfront payment as well as contingent milestone payments. Read more.